

L03584-02702282 K2M

In re Application of: Cynthia K. French et al

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial	No.:	09/680,121		Group No.:	1642	RECEIVE!
Filed:		October 4, 20	00	Examiner:	Gary B. Nickol	NOV 2 6 2002
For:		PROSTATE (CANCER-SPECIF	IC MARKER		TECH CENTER 1600/2
		ONER FOR PATENT D.C. 20231	S			
		·	TRANSMI	TTAL LETTER		
1.	Trans	mitted herewith is a Ter	minal Disclaimer	in reference to the	e above-captioned	application.
2.	Other	Papers Enclosed:				·
	<u>X</u>	Terminal Disclaimer	Fee \$ 55.00 Char No. 150665	ge Orrick, Herrin	gton & Sutcliffe I	LLP Deposit Account
	_	37 C.F.R. § 1.17(r)	Fee \$			
		37 C.F.R. § 1.17(m)	Fee \$			
STAT	CUS					
3.	A veri	cant is: <u>X</u> a small filed statement claiming ached <u>x</u> al			ity	
		*	CERTIFICATE OF N	1AILING (37 C.F.R. §1.1	0)	
I hereby o	certify that th sufficien	this paper (along with any referred it postage as 'Express Mail Post Of	to as being attached or en	closed) is being deposited	with the United States Po	stal Service on the date shown Washington, D.C. 20231.
EV 2078 Express N	72382 US Mail Label			Lynne Fulmer Name of Person I	<u> </u>	
Date of D	er 20 2002 Deposit			Signature of Pers	on Mailing Paper	
DOCSOC	11-130436	1				

FEE	P	A	\mathbf{Y}	N	1E	ľ	T
-----	---	---	--------------	---	----	---	---

 Attached i	is our	check	in the	sum of	f \$ _	
					· 	

X Charge Orrick, Herrington & Sutcliffe LLP Deposit Account No. 150665 the sum of \$55.00.

FEE DEFICIENCY

- 7. Authorization to charge additional fees and instructions as to over payment:
- X The Commissioner is hereby authorized to charge any additional fees which may be required or credit any over payment Charge Orrick, Herrington & Sutcliffe LLP Deposit Account No. 150665

Respectfully submitted,

ORRICK, HERRINGTON & SUTCLIFFE LLP

Dated: November 20, 2002

949/567-6710 Facsimile

KTM/lf 4 Park Plaza, Suite 1600 Irvine, CA 92614 949/567-6700 X 7740 Telephone Kurt T. Mulville Reg. No. 37,194

Patent 270/228

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mn	re	App	lication	of:	

Cynthia K. French, et al.

Serial No.:

09/680,121

Filed: October 4, 2000

PROSTATE CANCER-SPECIFIC

MARKER

Group Art Unit: 1642

Examiner: Gary B. Nickol

RECEIVED

NOV 2 6 2002

TECH CENTER 1600/2900

TERMINAL DISCLAIMER

Commissioner for Patents Washington, D.C. 20231

Sir:

I, Kurt T. Mulville, represent that I am an attorney of record for the above-identified application. The above-identified invention has been assigned to DIAGNOSTIC PRODUCTS CORPORATION. DIAGNOSTIC PRODUCTS CORPORATION is the owner of 100% interest in the above-identified invention. DIAGNOSTIC PRODUCTS CORPORATION is owner of 100% interest in United States Patent No. 6,218,523, issued April 17, 2001.

Assignee hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the statutory expiration date of U. S. Patent No. 6,218,523.

CERTIFICA'	TE OF	MAHING	/37 C E P	61 10)
CENTILICIA	11.01	MULLINIA	131 (.1.1.	41.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

EV 207872382 US

Express Mail Label No.

November 20 2002

Date of Deposit

DOCSOC1:130431.1

L03584-02702282 K2M

11/25/2002 NMOHAMM1 00000101 150665

09680121

55.00 CH 03 FC:2814

Lynne Fulmer Name of Person Mailing Paper

Signature of Person Mailing Paper

Patent

Attorney Docket: 270/228

Moreover, assignee hereby agrees that any patent so granted on the above-identified application

shall be enforceable only for and during such period that the legal title to said patent shall be the same as

the legal title to United States Patent No. 6,218,523, this agreement to run with any patent granted on

the above-identified application and to be binding upon assignee, successors, or assigns.

Assignee does not disclaim any terminal part of any patent granted on the above-identified

application prior to the expiration date of the full statutory term of United States Patent No. 6,218,523

in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found

invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.312(a), has all

claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its

statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title

stated above.

Respectfully submitted,

ORRICK, HERRINGTON & SUTCLIFFE LLP

Dated: November 20, 2002

By: Kurt T. Mulville

Reg. No. 37,194

4 Park Plaza, Suite 1600 Irvine, CA 92614

949/567-6700 X 7740 Telephone

949/567-6710 Facsimile

1